Mobile Menu Mobile Close

Search

LEARN MORE AT UKONIQ.COM LEARN MORE AT UKONIQ.COM

LEARN MORE ABOUT OUR FEARLESS PURSUIT

LATEST NEWS

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology

NEW YORK, June 18, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II global, active controlled, Phase 3 trials evaluating ublituximab, the Company’s investigational novel, glycoengineered anti-CD20 monoclonal antibody,

Read More >

GET INVESTOR
INFORMATION

HEAR OUR
STORY

READ OUR
PUBLICATIONS

EXPLORE OUR
PIPELINE

JOIN OUR
TEAM

HEAR OUR
STORY

EXPLORE OUR
PIPELINE

READ OUR
PUBLICATIONS

JOIN OUR
TEAM

GET INVESTOR
INFORMATION

LATEST NEWS

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology

NEW YORK, June 18, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II global, active controlled, Phase 3 trials evaluating ublituximab, the Company’s investigational novel, glycoengineered anti-CD20 monoclonal antibody,

Read More >
logo

Email Us 1-877-575-TGTX (8489)

©2021 TG Therapeutics, Inc. All rights reserved.

You are now leaving TGTherapeutics.com, a website wholly owned and operated by TG Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. TG Therapeutics, Inc., does not endorse or influence the content of websites that are not owned or operated by TG Therapeutics, Inc.

CONTINUE Return to tgtherapeutics.com